9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Estimated reading time: < 1 min

Condition: Advanced Solid Tumors

Estimated Enrollment: 60

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Determine the maximum tolerated dose (MTD), evaluate the pharmacokinetic profiles,  Safety, evaluate pharmacodynamic relationships,  ,

Interventions: OSI-930 and erlotinib,

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: April 2010

Completion Date: July 2010

Last  Posted Date: September 27, 2011

Location: H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Website Link: https://ClinicalTrials.gov/show/NCT00603356

Was this article helpful?
Dislike 0